MedTrace Logo

General Movement Assessment - Ancillary Study to SafeBoosC III Trial

NCT04555915 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2022-07-13

No results posted yet for this study

Summary

In course of the SafeBoosC III trial, we would like to analyse routinely performed GMA as secondary outcome parameter in an ancillary observational study.

First aim is to analyse in surviving neonates included into the SafeboosC III trial any differences between the experimental group group and control group in Global-GMA at term age.

Second aim is to investigate GMOS at term age and if available GMA at 9-16 weeks corrected age.

Conditions

  • General Movement Assessment

Interventions

OTHER

Monitoring of cerebral oxygenation

Modify cardio-respiratory support to avoid cerebral hypoxia

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Gerhard Pichler, MD · Medical University of Graz

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04555915 on ClinicalTrials.gov